Toll Free: 1-888-928-9744
Published: Feb, 2016 | Pages:
67 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Down Syndrome - Pipeline Review, H1 2016 Summary
Global Markets Direct's, 'Down Syndrome - Pipeline Review, H1 2016', provides an overview of the Down Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Down Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Down Syndrome and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Down Syndrome - The report reviews pipeline therapeutics for Down Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Down Syndrome therapeutics and enlists all their major and minor projects - The report assesses Down Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Down Syndrome Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Down Syndrome - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Down Syndrome pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Down Syndrome Overview 7 Therapeutics Development 8 Pipeline Products for Down Syndrome - Overview 8 Pipeline Products for Down Syndrome - Comparative Analysis 9 Down Syndrome - Therapeutics under Development by Companies 10 Down Syndrome - Therapeutics under Investigation by Universities/Institutes 11 Down Syndrome - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Unknown Stage Products 14 Down Syndrome - Products under Development by Companies 15 Down Syndrome - Products under Investigation by Universities/Institutes 16 Down Syndrome - Companies Involved in Therapeutics Development 17 AC Immune SA 17 Aelis Farma S.A.S. 18 Eisai Co., Ltd. 19 F. Hoffmann-La Roche Ltd. 20 NeuroNascent, Inc. 21 Transition Therapeutics Inc. 22 Down Syndrome - Therapeutics Assessment 23 Assessment by Monotherapy Products 23 Assessment by Target 24 Assessment by Mechanism of Action 26 Assessment by Route of Administration 28 Assessment by Molecule Type 30 Drug Profiles 32 ACI-24 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 APH-1104 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 basmisanil - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 D-217 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 donepezil hydrochloride - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 ELND-005 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 minocycline - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 NNI-351 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 NNI-362 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Pentylenetetrazol - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Small Molecule to Antagonize CB1R for Fragile X Syndrome and Down Syndrome - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Small Molecule to inhibit DYRK1A for CNS Diseases - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Small Molecules for Down Syndrome - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Small Molecules to Inhibit OLIG2 for Down Syndrome - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Stem Cell Therapy to Activate ZSCAN4 for Down Syndrome and Edwards Syndrome - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 xamoterol fumarate - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Down Syndrome - Recent Pipeline Updates 53 Down Syndrome - Discontinued Products 61 Down Syndrome - Product Development Milestones 62 Featured News & Press Releases 62 Feb 05, 2015: Neuronascent Announces Expanded Patent Coverage in Russia for Its Down Syndrome Therapeutics 62 Nov 20, 2014: Transition Therapeutics Announces Results from ELND005 Clinical Study in Adults with Down Syndrome 62 Apr 07, 2014: Transition Therapeutics Announces Development Update 62 Sep 04, 2013: Transition Therapeutics Announces Dosing of the First Patient in Phase 2a Study of ELND005 in Down Syndrome 64 Sep 03, 2013: Elan Announces Dosing of First Patient in Phase 2a Trial of ELND005 (Scyllo-inositol) in Down Syndrome 64 Feb 27, 2013: Roche Provides Update On Its Clinical Candidate For Down Syndrome 64 Appendix 66 Methodology 66 Coverage 66 Secondary Research 66 Primary Research 66 Expert Panel Validation 66 Contact Us 66 Disclaimer 67
List of Tables
Number of Products under Development for Down Syndrome, H1 2016 8 Number of Products under Development for Down Syndrome - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Clinical Stage Development, H1 2016 12 Comparative Analysis by Early Stage Development, H1 2016 13 Comparative Analysis by Unknown Stage Development, H1 2016 14 Products under Development by Companies, H1 2016 15 Products under Investigation by Universities/Institutes, H1 2016 16 Down Syndrome - Pipeline by AC Immune SA, H1 2016 17 Down Syndrome - Pipeline by Aelis Farma S.A.S., H1 2016 18 Down Syndrome - Pipeline by Eisai Co., Ltd., H1 2016 19 Down Syndrome - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 20 Down Syndrome - Pipeline by NeuroNascent, Inc., H1 2016 21 Down Syndrome - Pipeline by Transition Therapeutics Inc., H1 2016 22 Assessment by Monotherapy Products, H1 2016 23 Number of Products by Stage and Target, H1 2016 25 Number of Products by Stage and Mechanism of Action, H1 2016 27 Number of Products by Stage and Route of Administration, H1 2016 29 Number of Products by Stage and Molecule Type, H1 2016 31 Down Syndrome Therapeutics - Recent Pipeline Updates, H1 2016 53 Down Syndrome - Discontinued Products, H1 2016 61
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.